A Randomized Trial of Cvac (Autologous Dendritic Cells Pulsed With Recombinant Human Fusion Protein [Mucin 1-glutathione S-transferase] Coupled to Oxidized Polymannose) as Maintenance Treatment in Patients With Epithelial Ovarian Cancer (EOC) in Complete Remission Following First-line Chemotherapy (A) and Patients With EOC in Second Remission (B)

Trial Profile

A Randomized Trial of Cvac (Autologous Dendritic Cells Pulsed With Recombinant Human Fusion Protein [Mucin 1-glutathione S-transferase] Coupled to Oxidized Polymannose) as Maintenance Treatment in Patients With Epithelial Ovarian Cancer (EOC) in Complete Remission Following First-line Chemotherapy (A) and Patients With EOC in Second Remission (B)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 Jan 2017

At a glance

  • Drugs Cancer vaccine MUC-1 (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CANVAS
  • Sponsors Prima Biomed
  • Most Recent Events

    • 02 Mar 2015 Prima Biomed has ceased recruitment in this study (in part due to slow patient accrual) to focus on the development of LAG-3 related product candidates, according to a media release.
    • 02 Mar 2015 Status changed from recruiting to discontinued, according to a Prima Biomed media release.
    • 19 Aug 2014 According to a Prima BioMed media release, the results of this trial will be presented at the Society for Immunotherapy of Cancer 29th Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top